PCM
INZY

Penserra Capital Management’s Inozyme Pharma INZY Stock Holding History

Penserra Capital Management’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-540
Closed -$6K – 1448
2021
Q3 		$6K Buy
540
+5
+0.9% +$78 ﹤0.01% 1401
2021
Q2 		$9K Buy
535
+5
+0.9% +$87 ﹤0.01% 1278
2021
Q1 		$10K Sell
530
-5
-0.9% -$110 ﹤0.01% 1035
2020
Q4 		$11K Buy
+535
New +$12.7K ﹤0.01% 915

Other funds holding INZY

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Penserra Capital Management's INZY Position: Q4 2021 in Review

Penserra Capital Management sold out of Inozyme Pharma (INZY) in Q4 2021, closing a stake of 540 shares — an estimated $6K sold.

Penserra Capital Management first reported a position in INZY in Q4 2020 and held it in 4 quarters. The position peaked at $11K in Q4 2020. 51 funds tracked by Wall St. Rank hold INZY as of Q4 2021.

  • Penserra Capital Management reported no remaining Inozyme Pharma position as of Q4 2021 after selling out during the quarter.
  • Penserra Capital Management sold 540 Inozyme Pharma shares in Q4 2021, an estimated $6K.
  • Penserra Capital Management first reported a position in Inozyme Pharma in Q4 2020 and held it in 4 quarters.
  • Penserra Capital Management's Inozyme Pharma position peaked at $11K in Q4 2020.
  • 51 funds tracked by Wall St. Rank held Inozyme Pharma as of Q4 2021.

Based on Penserra Capital Management's 13F filing for Q4 2021, filed 15 Feb 2022.